POINT Biopharma, Isotopia Ink Lutetium-177 Clinical Supply Agreement


POINT Biopharma Global Inc PNT and Isotopia Molecular Imaging Limited have signed a clinical supply agreement for the medical radioisotope no-carrier-added Lutetium-177 (Lu-177), a therapeutic isotope used in POINT's pipeline.

  • The 6.6-day half-life of Lu-177 is sufficiently short for use with various radiopharmaceuticals and long enough to minimize decay loss during the preparation and shipping of the radiopharmaceutical. 
  • Lu-177 damages tumors when bound to disease-specific targeting therapeutics, such as POINT's PSMA targeting drug candidate PNT2002 for metastatic castration-resistant prostate cancer (mCRPC). 
  • Isotopia has developed a GMP method to produce a highly pure form of n.c.a. Lu-177. Isotopia's Lu-177 contains no metastable Lu-177m, eliminating cost-intensive clinical waste management. 
  • Isotopia's Lu-177 will be used at POINT's Indianapolis facility to manufacture its therapeutic radioligand therapies.
  • Price Action: PNT shares are up 0.50% at $8.11 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!